Deerfield Management Company, L.P. (Series C) Avidity Biosciences, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.87 - $9.37 $91,107 - $175,293	18,708 New	18,708 $169,000
Q3 2021 Nov 15, 2021	SELL	$18.16 - $25.21 $10.2 Million - $14.1 Million	-560,132 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.62 - $29.26 $2.08 Million - $3.11 Million	106,159 Added 23.38%	560,132 $13.8 Million
Q4 2020 Feb 16, 2021	SELL	$24.73 - $35.12 $499,867 - $709,880	-20,213 Reduced 4.26%	453,973 $11.6 Million
Q3 2020 Nov 16, 2020	SELL	$23.35 - $35.94 $9.41 Million - $14.5 Million	-402,825 Reduced 45.93%	474,186 $13.3 Million
Q2 2020 Aug 14, 2020	BUY	$26.62 - $31.5 $23.3 Million - $27.6 Million	877,011 New	877,011 $24.8 Million

Others Institutions Holding RNA

# of Institutions

250

Shares Held

107M

Call Options Held

224K

Put Options Held

161K

Price T Rowe Associates Inc Baltimore, MD

10.6M
Shares

$365 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

9.43M
Shares

$324 Million
0.0% of portfolio
Black Rock Inc. New York, NY

8.62M
Shares

$296 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

8.13M
Shares

$279 Million
5.95% of portfolio
Wellington Management Group LLP Boston, MA

7.03M
Shares

$241 Million
0.06% of portfolio

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.79B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account